SYRE
Spyre Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$84.72
+6.03%0
Insider buys (3m)
41
Insider sells (3m)
-$16.9M
Net value (3m)
-12.1%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | M-Exempt | 28,933 | $15 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 229 | $94 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 3,071 | $93 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 2,100 | $92 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 1,500 | $90 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 600 | $89 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | M-Exempt | 7,500 | $15 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 17,500 | $90 |
| Oct 2, 2026 | Burrows Scott L · officer: Chief Financial Officer | M-Exempt | 17,500 | $15 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 100 | $94 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 4,990 | $93 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 3,989 | $92 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 2,638 | $91 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 2,683 | $90 |
| Oct 2, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 600 | $89 |
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | Sale | 2,600 | $93 |
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | Sale | 2,100 | $93 |
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | Sale | 7,228 | $91 |
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | Sale | 16,605 | $90 |
| Oct 2, 2026 | King-Jones Heidy · officer: See Remarks | Sale | 400 | $89 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 2,016 | $88 |
| Sep 3, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 400 | $89 |
| Sep 3, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 3,700 | $88 |
| Sep 3, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 8,400 | $87 |
| Sep 3, 2026 | Turtle Cameron · director, officer: Chief Executive Officer | Sale | 2,500 | $86 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 18,232 | $89 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 200 | $89 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 4,384 | $87 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | Sale | 900 | $86 |
| Sep 3, 2026 | Burrows Scott L · officer: Chief Financial Officer | M-Exempt | 7,500 | $15 |
Institutional positioning
13F filings over the trailing two quarters
New 145Increased 167Reduced 106Sold out 26
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 13,026,187 | Aug 13, 2026 |
| FMR LLC | Increased | 11,781,024 | May 15, 2026 |
| BlackRock, Inc. | Increased | 6,506,605 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 5,521,221 | May 13, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 4,319,496 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Increased | 4,251,996 | Aug 14, 2026 |
| RTW INVESTMENTS, LP | Unchanged | 4,171,996 | May 15, 2026 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Unchanged | 4,018,101 | May 15, 2026 |
| Paradigm Biocapital Advisors LP | Increased | 3,840,778 | Aug 14, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 3,783,225 | May 29, 2026 |
| VR ADVISER, LLC | Unchanged | 3,685,448 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 3,448,681 | Aug 13, 2026 |
| STATE STREET CORP | Increased | 3,057,416 | Sep 22, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,057,401 | May 15, 2026 |
| VR Adviser, LLC | Reduced | 2,985,448 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 2, 2026